Experts admit to preferring docetaxel chemotherapy over lutetium for symptomatic mCRPC patients primarily because it 'feels' more aggressive and is logistically faster to administer. This decision is based on perception and convenience rather than strong clinical evidence comparing the agents in this specific context.

Lutetium faces criticism for its fixed 6-cycle regimen, which may be suboptimal as the PSMA target diminishes with ADT. However, this critique is rarely applied to other drugs like PARP inhibitors, which are given until progression. This highlights a double standard and the tension between using a fixed regimen for regulatory approval versus finding the optimal dose in practice.

In a data-free zone, a survey of 78 US oncologists revealed an emerging consensus to wait six months before re-challenging with EV-Pembro after prior immunotherapy. This demonstrates how clinical practice norms can form around arbitrary time points when definitive evidence on optimal treatment-free intervals is lacking.

The common practice of switching from one ARPI to another upon disease progression is now considered ineffective for most patients. With the advent of proven alternatives like chemotherapy and lutetium, using an "ARPI switch" as the sole control arm in clinical trials is no longer ethically or scientifically sound.

If lutetium-PSMA is approved and used upfront in hormone-sensitive disease, clinicians may become more comfortable with radioligands generally. This could lead them to use the enzalutamide-radium combination more frequently later on, paradoxically increasing radium's use by flipping the current treatment sequence.

Clinicians may be biased towards lutetium-PSMA because it causes significant PSA drops, which radium-223 does not. This observable metric may not reflect superior overall efficacy, as radium's survival benefit is proven and it may even have unique synergistic potential with drugs like enzalutamide through different biological pathways.

Despite data from kidney cancer showing immunotherapy re-challenge is often ineffective, oncologists admit to using it in urothelial cancer. This highlights a clinical conflict where the desire to use a powerful drug class outweighs the lack of supporting evidence, especially in specific, confusing patient scenarios.

While Lutetium shows promise in hormone-sensitive prostate cancer, experts raise concerns about potential late-effect toxicities for patients surviving many years. This contrasts with docetaxel, where toxicity is acute and resolves after treatment, highlighting an unknown long-term risk-benefit profile for new radioligand therapies.

Expert analysis reveals a key weakness in many Lutetium-PSMA trials: the choice of the control arm. By comparing the novel therapy against a less-than-optimal standard of care, the trials may have been designed for an "easy win," dampening expert enthusiasm and raising questions about its true superiority over other potent hormonal therapies.